Search | Page 12 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. TCRαβ+/CD19+ Depleted Haploidentical HSCT + Zoledronate

    ... period to treat pediatric patients with relapsed or refractory hematologic malignancies or high risk solid tumors. ... curative transplant Relapsed or primary therapy- refractory AML with bone marrow blast < 20% High-risk ...

    Clinical Trial last updated 04/29/2016 - 4:35pm.

  2. Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States.

    ... of SES on survival was more apparent for patients with refractory anemia with ringed sideroblasts-patients residing in ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Historical perspectives on myelodysplastic syndromes

    ... etiology and nature of disorders described as " refractory anemia ", "preleukemia", and with other terminology ...

    Research Article last updated 10/02/2012 - 9:52am.

  4. A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes.

    ... the United States, or in Europe, female in gender, had refractory anemia (RA)/RA with ringed sideroblasts (RARS) or RA ...

    Research Article last updated 07/09/2013 - 3:26pm.

  5. Aplastic anemia: therapeutic updates in immunosuppression and transplantation

    ... eltrombopag, is showing promising activity in refractory cases. The most recent advances in HSCT and IST in SAA are ...

    Research Article last updated 01/02/2013 - 2:25pm.

  6. Eltrombopag Added to IST Yields Encouraging Results

    ... responded to immunosuppressive therapy (IST). These refractory patients were continuing to require weekly transfusions for ...

    Interview last updated 05/24/2017 - 7:44am.

  7. A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation (AML)

    ... Cohort 1 will enroll up to 26 patients with relapsed or refractory AML and confirmed FLT3 mutation without prior exposure to a FLT3 ... Cohort 2 will enroll up to 12 patients with relapsed or refractory AML and confirmed FLT3 mutation with prior exposure to a FLT3 ...

    Clinical Trial last updated 05/09/2016 - 4:09pm.

  8. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... and iron chelation. Management of progressive or refractory disease: There are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options ...

    Research Article last updated 02/04/2014 - 1:37pm.

  9. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... and iron chelation. MANAGEMENT OF PROGRESSIVE OR REFRACTORY DISEASE: At the present time, there are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... and iron chelation. Management of progressive or refractory disease: At the present time there are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options ...

    Research Article last updated 07/31/2012 - 2:02pm.